Molecular Oncology Almanac
API
Approvals
Organizations
About
Contact
Cervical Adenocarcinoma
About
Mappings
OncoTree
:
Cervical Adenocarcinoma (oncotree:CEAD)
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
Type
Biomarker(s)
Cancer type
Therapy(ies)
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Carboplatin
,
Paclitaxel
,
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Bevacizumab
,
Carboplatin
,
Paclitaxel
,
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Cisplatin
,
Paclitaxel
,
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Bevacizumab
,
Cisplatin
,
Paclitaxel
,
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Carboplatin
,
Paclitaxel
,
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Bevacizumab
,
Carboplatin
,
Paclitaxel
,
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Bevacizumab
,
Carboplatin
,
Paclitaxel
,
Pembrolizumab
Sensitivity (+)
PD-L1 (CPS) >= 1
Cervical Adenocarcinoma
Carboplatin
,
Paclitaxel
,
Pembrolizumab